AstraZeneca (AZN) Stock Price, News & Analysis

Company Overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Key Stats

• Today's Range: $65.42 to $66.03
• 50-Day Range: $63.20 to $77.44
• 52-Week Range: $60.47 to $87.68
• Volume: 1.16 million shs
• Average Volume: 5.31 million shs
• Market Capitalization: $203.28 billion
• P/E Ratio: 31.37
• Dividend Yield: 1.49%
• Price Target: $89.75
• Consensus Rating: Moderate Buy

AstraZeneca Stock Analysis - MarketRank™

AstraZeneca scored higher than 75% of companies evaluated by MarketBeat, and ranked 281st out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

AstraZeneca has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 14.84%

Earnings Growth

Earnings for AstraZeneca are expected to grow by 14.84% in the coming year, from $4.11 to $4.72 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AstraZeneca is 31.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.63.

Price to Earnings Ratio vs. Sector

The P/E ratio of AstraZeneca is 31.41, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 86.68.

Price to Earnings Growth Ratio

AstraZeneca has a PEG Ratio of 1.19. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

AstraZeneca has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.32% of the outstanding shares of AstraZeneca have been sold short.

Short Interest Ratio / Days to Cover

AstraZeneca has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AstraZeneca has recently increased by 35.95%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

AstraZeneca pays a meaningful dividend of 1.47%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

AstraZeneca does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of AstraZeneca is 46.89%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 20.76% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.32% of the outstanding shares of AstraZeneca have been sold short.

Short Interest Ratio / Days to Cover

AstraZeneca has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AstraZeneca has recently increased by 35.95%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.29

News Sentiment

AstraZeneca has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 38 news articles for AstraZeneca this week, compared to 20 articles on an average week.

Search Interest

Only 22 people have searched for AZN on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.

MarketBeat Follows

Only 11 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is a decrease of -59% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AstraZeneca insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 20.35% of the stock of AstraZeneca is held by institutions.

AZN Stock Analysis - Frequently Asked Questions

How have AZN shares performed this year?

AstraZeneca's stock was trading at $67.35 at the beginning of 2024. Since then, AZN stock has decreased by 2.5% and is now trading at $65.64.
View the best growth stocks for 2024 here.

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) released its quarterly earnings results on Tuesday, November, 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca's quarterly revenue was up 18.0% compared to the same quarter last year.

When did AstraZeneca's stock split?

Shares of AstraZeneca split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were distributed to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Does AstraZeneca have any subsidiaries?

The following companies are subsidiaries of AstraZeneca: Alexion Pharmaceuticals, Takeda Respiratory Business, AcertaPharma, ZS Pharma, Almirall, Pearl Therapeutics, Omthera Pharmaceuticals, and others.

How do I buy shares of AstraZeneca?

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Chevron (CVX), BlackRock (BLK), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Bristol-Myers Squibb (BMY) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 12/31/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AZN
• CUSIP: N/A
• CIK: 901832
• Web: www.astrazeneca.com
• Phone: 442037495000
• Fax: 44-12-2335-2858
• Employees: 89,900
• Year Founded: 1999

Price Target and Rating

• Average Stock Price Target: $89.75
• High Stock Price Target: $97.00
• Low Stock Price Target: $82.00
• Potential Upside/Downside: +36.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $2.09
• Trailing P/E Ratio: 31.37
• Forward P/E Ratio: 15.95
• P/E Growth: 1.19
• Net Income: $5.96 billion
• Net Margins: 12.68%
• Pretax Margin: 15.47%
• Return on Equity: 30.01%
• Return on Assets: 11.42%

Debt

• Debt-to-Equity Ratio: 0.71
• Current Ratio: 0.93
• Quick Ratio: 0.71

Sales & Book Value

• Annual Sales: $51.21 billion
• Price / Sales: 3.97
• Cash Flow: $5.31 per share
• Price / Cash Flow: 12.34
• Book Value: $12.63 per share
• Price / Book: 5.19

Miscellaneous

• Outstanding Shares: 3,100,634,000
• Free Float: N/A
• Market Cap: $203.31 billion
• Optionable: Optionable
• Beta: 0.45